OakChart

Alpha Cognition Inc

ACOGHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 7:55 AM ET

8.75+0.02 (0.23%)
2026-11-11 14:22 CET
Market cap
135.59 USD m
Revenue, TTM
15.26 USD m
Net income, TTM
-23.44 USD m
Free cash flow, TTM
-30.99 USD m
EPS diluted, TTM
-1.12
P/E
-
Compare

Price

ACOG against its 20, 50 and 200-day averages
2050200beatmissearnings
6.008.0010.00184K367KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ACOGclose 8.7520-day 8.5650-day 8.77200-day 7.268.75

13.7% under 10.14 on 24 Aug 2026. Last 15 sessions, 17.2% high to low

Profile

ACOG
52-week range, 75% of the way up
4.5010.14

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal ("ALPHA-1062IN") formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Employees71
IPOJun 28, 2021
Beta2.32
ATR, 14d0.49
Rel volume0.00
Short float2.90%
Insider own8.37%
Inst own83.60%

Snapshot

6 groups

Valuation

Index-
Market Cap190.56M
Enterprise Value149.12M
Income-23.44M
Sales15.26M
Book/sh2.43
Cash/sh1.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees71
IPOJun 28, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S12.49
P/B3.60
P/C4.60
P/FCF-
EV/EBITDA-
EV/Sales9.77
Quick Ratio8.00
Current Ratio9.00
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.12
EPS next Y-0.62
EPS next Q-0.34
EPS this Y-12.68%
EPS next Y53.22%
EPS next 5Y-
EPS past 3/5Y35.73% 45.28%
Sales past 3/5Y- -
EPS Y/Y TTM31.08%
Sales Y/Y TTM232.74%
EPS Q/Q38.34%
Sales Q/Q267.56%
EarningsNov 11 AMC
EPS/Sales Surpr.-2.01% 36.86%

Ownership

Insider Own8.37%
Insider Trans86.14%
Inst Own83.60%
Inst Trans0.97%
ROA-42.76%
ROE-55.25%
ROIC-44.26%
Gross Margin89.24%
Oper. Margin-190.62%
Profit Margin-153.61%
SMA202.23%
SMA50-0.26%
SMA20020.57%
Trades-

Technical

Shs Outstand21.77M
Shs Float14.23M
Short Float2.90%
Short Ratio3.27
Short Interest0.41M
52W High10.14 -13.71%
52W Low4.50 94.44%
Volatility6.99% 6.02%
ATR (14)0.49
RSI (14)51.70
Beta2.32
Rel Volume0.00
Avg Volume126.04K
Volume12

Performance

Perf Week2.58%
Perf Month-0.57%
Perf Quarter1.39%
Perf Half Y47.06%
Perf YTD34.62%
Perf Year42.97%
Perf 3Y35.62%
Perf 5Y-62.15%
Perf 10Y-
Recom1.20
Target Price18.00
Prev Close8.73
Price8.75
Change %0.23%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Aug 20, 2026InitiatedRB. Riley SecuritiesBuy$21+140.0%
Jul 10, 2026InitiatedRRaymond JamesOutperform$20+128.6%
May 29, 2026InitiatedMMaxim GroupBuy$12+37.1%
Apr 17, 2026InitiatedCCraig HallumBuy$14+60.0%
Mar 18, 2025InitiatedHH.C. WainwrightBuy$20+128.6%

Peers

Mkt cap
TickerCompanyMkt cap
AVXLAnavex Life Sciences Corp108.46M
AXSMAxsome Therapeutics Inc7.47B
CGTXCognition Therapeutics Inc63.53M
ANVSAnnovis Bio Inc35.27M
ACADAcadia Pharmaceuticals Inc3.15B
PRTAProthena Corp Plc428.25M
INMBINmune Bio Inc33.95M
ATHEAlterity Therapeutics Ltd ADR44.31M
ALZNAlzamend Neuro Inc6.51M
SUPNSupernus Inc5.97B

Insider trading

latest 14 of 53
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Opaleye Management Inc.10% OwnerOct 22 '26Buy8.3317,117142,5263,277,011Oct 26 04:51 PM
Opaleye Management Inc.10% OwnerOct 23 '26Buy8.2314,973123,2943,291,984Oct 26 04:51 PM
Opaleye Management Inc.10% OwnerOct 15 '26Buy8.4322,657190,9743,245,611Oct 19 05:34 PM
Opaleye Management Inc.10% OwnerOct 16 '26Buy8.2314,283117,6023,259,894Oct 19 05:34 PM
Opaleye Management Inc.10% OwnerOct 01 '26Buy8.6919,050165,6343,222,954Oct 02 04:05 PM
Opaleye Management Inc.10% OwnerSep 24 '26Buy8.5718,337157,0823,190,478Sep 28 07:57 PM
Opaleye Management Inc.10% OwnerSep 25 '26Buy8.4713,426113,7183,203,904Sep 28 07:57 PM
Opaleye Management Inc.10% OwnerSep 16 '26Buy8.5180,170682,5913,172,141Sep 16 05:57 PM
Opaleye Management Inc.10% OwnerSep 14 '26Buy8.7040,373351,0843,088,596Sep 16 05:57 PM
Opaleye Management Inc.10% OwnerSep 15 '26Buy8.543,37528,8313,091,971Sep 16 05:57 PM
Wills Robert JamesDirectorAug 21 '26Buy9.6210,00096,20032,241Aug 24 02:52 PM
Opaleye Management Inc.10% OwnerAug 03 '26Buy8.0050,000400,0003,048,223Aug 04 04:50 PM
Opaleye Management Inc.10% OwnerJul 31 '26Buy7.922,90022,9762,998,223Aug 04 04:50 PM
Opaleye Management Inc.10% OwnerJul 24 '26Buy7.901301,0272,995,323Jul 28 04:05 PM

Held by

AUM
TickerCompanyAUM
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.25B

News

latest 14 of 168
  • Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf (Business Wire) +7.36%
  • Alpha Cognition to Participate in Upcoming Investor Events (Business Wire)
  • Alpha Cognition's Zunvale Ramp Faces A Payer Test As Street Models Slower Growth (Earnings Whispers)
  • Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update (Business Wire)
  • Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL (Business Wire)
  • Loading…
  • Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress (Business Wire)
  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care (Business Wire)
  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 (Newsfile)
  • Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update (Business Wire)
  • Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11--0.335--7.046
2026Q22026-08-13-0.400-0.392-0.4006.004.385
2026Q12026-05-14-0.320-0.387-0.3213.533.423
2025Q42026-03-26-0.313-0.270-0.3152.803.202
2025Q32025-11-13-0.080-0.430-0.0822.802.032
2025Q22025-08-14-0.650-0.460-0.6551.681.662
2025Q12025-05-15-0.130-0.580-0.1252.910.502
2024Q42025-03-31-0.510-0.630-0.5050.000.002
2024Q32024-11-15-0.310-1.000-0.3090.000.001
2024Q22024-08-12-0.250-1.000-0.3520.000.001
2026Q4---0.280--9.026
2027Q1---0.250--9.484
2027Q2---0.215--10.924
2027Q3---0.135--12.924
2027Q4---0.050--15.474
2028Q1--0.130--19.302

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-3.750--3.6490.000.00
2024FY-2.020-1.605-2.0400.000.00
2025FY-1.170-1.115-1.17510.2210.61
2026FY--1.318--25.71
2027FY--0.617--49.26
2028FY-0.604--86.10
2029FY-2.583--144.26
2030FY-1.750--126.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-286007.046.308.00
2026Q3S2026-08-196417.046.308.00
2026Q3S2026-08-186417.046.308.00
2026Q3S2026-08-145416.856.307.38
2026Q3S2026-08-135106.024.878.45
2026Q3S2026-08-045106.024.878.45
2026Q3S2026-07-295206.024.878.45
2026Q3S2026-07-085306.024.878.45
2026Q3S2026-06-114306.315.308.45
2026Q3S2026-05-284206.245.108.45
2026Q3S2026-05-213206.555.108.45
2026Q3S2026-05-153206.505.108.29
2026Q3S2026-04-243106.335.108.29
2026Q3S2026-04-163015.665.106.29

Estimate history

EPS, annual-0.697-2.732-24.04-9.162-4.441-3.649-2.04-1.179-1.1215
Period20182019202020212022202320242025TTM
EPS, quarterly-0.352-0.309-0.505-0.125-0.655-0.082-0.315-0.321-0.404
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000010.2215.26
Period20182019202020212022202320242025TTM
Sales, quarterly0002.9291.6582.8412.7933.5346.093
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0480.0410.2412.4242.4415.04516.0221.74221.774
Period20182019202020212022202320242025MRQ
Shares, quarterly6.026.03416.0216.0216.02316.25121.74221.77421.774
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Total Revenue15.2610.220.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.641.970.080.080.090.090.080.000.00
Gross Profit13.628.25-0.08-0.08-0.09-0.09-0.080.000.00
Selling, General and Administrative Excl. Other42.7130.9111.939.7913.4411.485.620.070.10
Research and Development4.251.873.925.008.727.974.67--
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-29.09-22.66-12.01-9.88-13.54-11.57-5.71-0.07-0.10
Interest Expense--0.110.070.060.530.770.000.00
Unusual Expense-3.78-0.093.164.10-1.827.50-0.670.000.00
Net Income Before Taxes-23.44-20.67-14.79-13.77-12.07-19.55-5.78-0.06-0.09
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-23.44-20.67-14.79-13.77-12.07-19.55-5.78-0.06-0.09
Net Income From Continuing Operations-23.44-20.67-14.79-13.77-12.07-19.55-5.78-0.06-0.09
Net Income-23.44-20.67-14.79-13.77-12.07-19.55-5.78-0.06-0.09
EPS (Recurring)-1.22-1.18-1.73-2.89-4.91-6.70-25.99-0.06-2.73
EPS (Basic, Before Extraordinaries)-1.10-1.17-2.04-3.65-4.44-9.16-24.04-0.06-2.73
EPS (Diluted)-1.12-1.18-2.04-3.65-4.44-9.16-24.04-0.06-2.73
EBITDA-28.92-22.60-11.93-9.79-13.44-11.48-5.62-0.07-0.10
Non-Operating Income (Expense)1.871.900.390.28-0.290.050.020.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.124.920.422.371.711.790.550.020.04
Price To Sales Ratio10.3011.25-------
Gross Margin89.2480.69-------
Operating Margin-190.62-221.72-------
Net Margin-153.61-202.24-------
Shares Outstanding21.7721.7416.025.052.442.420.241.020.04
Market Capitalization135.59135.5991.4850.2113.0460.0045.06--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue6.093.532.792.841.662.930.000.00
Cost of Goods Sold Incl. D&A0.420.300.280.640.550.840.020.02
Gross Profit5.673.232.512.201.112.08-0.02-0.02
Selling, General and Administrative Excl. Other13.4311.3310.447.516.855.772.642.38
Research and Development2.011.100.570.570.320.411.041.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.76-8.10-7.93-5.31-5.74-3.69-2.66-2.40
Interest Expense0.000.00---0.01-0.10
Unusual Expense1.46-1.12-0.44-3.675.17-1.153.32-0.59
Net Income Before Taxes-8.79-6.48-6.86-1.32-10.49-2.01-5.66-1.86
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.79-6.48-6.86-1.32-10.49-2.01-5.66-1.86
Net Income From Continuing Operations-8.79-6.48-6.86-1.32-10.49-2.01-5.66-1.86
Net Income-8.79-6.48-6.86-1.32-10.49-2.01-5.66-1.86
EPS (Recurring)-0.36-0.36-0.33-0.24-0.43-0.18-0.30-0.38
EPS (Basic, Before Extraordinaries)-0.40-0.30-0.32-0.08-0.65-0.13-0.51-0.31
EPS (Diluted)-0.40-0.32-0.32-0.08-0.65-0.13-0.51-0.31
EBITDA-7.65-8.07-7.90-5.30-5.73-3.68-2.64-2.38
Non-Operating Income (Expense)0.420.490.630.320.420.540.330.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.701.400.951.071.551.360.060.19
Price To Sales Ratio10.3011.1213.8314.1532.5927.68--
Gross Margin93.1091.4790.0077.4567.0871.19--
Operating Margin-127.29-229.11-283.75-186.99-346.08-125.87--
Net Margin-144.26-183.32-245.48-46.40-632.75-68.51--
Shares Outstanding21.7721.7721.7416.2516.0216.0216.026.03
Market Capitalization135.5985.27100.95101.11144.9178.5991.4860.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2018FY
Cash & Short Term Investments66.1148.561.492.0811.305.930.600.660.25
Short Term Receivables4.240.000.060.030.001.460.000.000.00
Inventories5.120.620.000.000.000.000.000.000.00
Other Current Assets3.321.070.370.220.870.310.010.000.01
Total Current Assets78.7950.251.922.3312.177.700.610.670.26
Net Property, Plant & Equipment0.330.030.000.000.010.010.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.390.410.530.610.700.730.000.000.00
Other Assets0.220.050.000.000.000.000.000.000.00
Total Assets79.7350.742.452.9512.888.440.610.670.26
Short Term Debt Incl. Current Port. of LT Debt0.000.911.221.211.080.020.000.000.00
Accounts Payable3.070.000.000.000.000.000.000.000.00
Other Current Liabilities6.062.441.402.850.733.550.030.030.03
Total Current Liabilities9.133.352.624.061.803.580.030.030.03
Long Term Debt0.000.000.000.000.003.190.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities8.078.294.540.212.051.650.000.000.00
Total Liabilities17.2011.647.164.273.858.420.030.030.03
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity62.5339.09-4.71-1.329.030.020.580.630.23
Total Shareholders Equity62.5339.09-4.71-1.329.030.020.580.630.23
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity62.5339.09-4.71-1.329.030.020.580.630.23
Total Liabilities & Stockholders Equity79.7350.742.452.9512.888.440.610.670.26
Book Value Per Share2.882.44-0.93-0.543.720.070.5715.524.84
Tangible Book Value Per Share2.862.41-1.04-0.793.44-2.960.5715.524.84
Full-Time Employees715756919---
Price to Book Ratio3.59-12.17-8.187.356.6431.67---
Return on Assets-31.69-55.61-509.80-152.52-183.38-127.10-9.83-19.50-
Return on Equity-39.75-86.03--313.21-432.14-1,785.27-10.33-20.83-
Return on Invested Capital-33.06-37.83---216.46-180.36-10.83-14.22-14.36
Quick Ratio8.0714.810.730.586.752.1521.1819.7910.12
Current Ratio8.6315.000.730.586.752.1521.1819.7910.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Net Income-23.19-20.67-14.79-13.77-12.07-19.55-5.78-0.06-0.09
Depreciation0.170.060.080.080.090.090.08--
Other Funds (Non Cash)0.464.857.196.450.009.770.590.020.04
Funds from Operations-22.56-15.76-7.51-7.24-11.98-9.68-5.11-0.05-0.05
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-8.11-4.62-0.24-1.562.73-0.20-0.33-0.010.01
Cash from Operating Activities-30.67-20.38-7.76-8.80-9.25-9.88-5.44-0.06-0.04
Capital Expenditures-6.20-0.29-0.030.00-0.00-0.06-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.520.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.20-0.29-0.030.00-0.000.46-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock39.1439.0951.148.190.0414.901.900.000.45
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock39.1439.0951.148.190.0414.901.900.000.45
Proceedsfrom Stock Options37.7837.7050.848.170.0012.461.900.000.45
Issuance or Reduction of Debt, Net0.01-0.913.790.000.00-0.023.980.000.00
Change in Long Term Debt0.000.004.090.000.000.000.000.000.00
Issuance of Long Term Debt0.000.004.090.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.04-0.070.040.000.000.000.000.00
Other Financing Activities Uses0.00-0.13-0.45-0.170.000.000.000.000.00
Cash from Financing Activities39.1638.2154.858.230.0414.885.880.000.45
Exchange Rate Effect--0.00-0.02-0.00-0.08---
Net Change in Cash2.2917.5447.07-0.59-9.225.380.43-0.050.41
Free Cash Flow-30.99-20.67-7.78-8.80-9.26-9.89-5.45-0.06-0.04
Preferred Dividends (Cash Flow)---0.000.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments41.4454.3166.1135.4639.4645.62
Short Term Receivables5.473.584.242.971.950.61
Inventories6.396.045.124.500.880.88
Other Current Assets4.394.413.322.772.351.00
Total Current Assets57.7068.3378.7945.7044.6548.12
Net Property, Plant & Equipment0.370.310.330.200.070.07
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets6.220.390.390.400.400.41
Other Assets0.220.220.220.000.000.01
Total Assets64.5269.2579.7346.3045.1248.61
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.191.433.070.840.750.82
Other Current Liabilities5.223.996.065.992.291.99
Total Current Liabilities6.415.439.136.833.042.81
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities5.156.378.075.5610.194.99
Total Liabilities11.5611.7917.2012.3913.237.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity52.9657.4662.5333.9131.9040.81
Total Shareholders Equity52.9657.4662.5333.9131.9040.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity52.9657.4662.5333.9131.9040.81
Total Liabilities & Stockholders Equity64.5269.2579.7346.3045.1248.61
Book Value Per Share2.432.642.882.091.992.55
Tangible Book Value Per Share2.152.622.862.061.972.52
Full-Time Employees--71---
Price to Book Ratio3.591.913.113.273.661.96
Return on Assets-42.76-42.66-31.69-75.87-84.80-44.70
Return on Equity-55.25-51.17-39.75-125.65-131.23-56.79
Return on Invested Capital-16.60-11.27-10.96-3.89-32.88-4.92
Quick Ratio8.0011.488.076.0314.4016.83
Current Ratio9.0012.608.636.6914.6917.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-8.72-6.48-6.69-1.31-10.71-2.01
Depreciation0.100.030.030.010.010.01
Other Funds (Non Cash)3.13-0.310.34-2.706.960.26
Funds from Operations-5.49-6.76-6.32-4.00-3.74-1.74
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.29-5.04-0.42-1.36-2.54-0.31
Cash from Operating Activities-6.77-11.80-6.74-5.35-6.28-2.04
Capital Expenditures-5.98-0.00-0.15-0.08-0.01-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.98-0.00-0.15-0.08-0.01-0.06
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock-0.000.0037.761.380.030.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.000.0037.761.380.030.00
Proceedsfrom Stock Options0.000.0037.410.370.000.00
Issuance or Reduction of Debt, Net0.000.000.010.00-0.02-0.91
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.00-0.00-0.040.08
Other Financing Activities Uses0.000.000.000.00-0.04-0.10
Cash from Financing Activities-0.000.0037.771.38-0.03-0.83
Net Change in Cash-12.75-11.8030.89-4.05-6.32-2.94
Free Cash Flow-6.87-11.80-6.89-5.43-6.29-2.11

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 10.22M
China2025: 3.43M
United States2025: 6.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.90%0.4M14.2M121.87K
2026-10-152.48%0.4M14.2M125.28K
2026-09-302.27%0.3M14.2M121.90K
2026-09-151.47%0.2M14.2M111.47K
2026-08-311.49%0.2M14.2M99.97K
2026-08-141.44%0.2M14.2M69.95K
2026-07-311.30%0.2M14.2M60.46K
2026-07-151.52%0.2M14.2M45.57K
2026-06-300.91%0.1M14.2M50.53K
2026-06-151.23%0.2M14.2M48.17K
2026-05-291.28%0.2M13.9M52.17K
2026-05-151.36%0.2M13.9M59.89K
2026-04-301.34%0.2M13.4M68.75K
2026-04-151.58%0.2M13.0M71.49K
2026-03-312.52%0.3M13.0M67.78K
2026-03-132.57%0.3M13.0M77.70K
2026-02-272.45%0.3M13.0M83.95K
2026-02-131.76%0.2M13.0M81.28K
2026-01-302.59%0.3M13.0M86.90K
2026-01-152.28%0.3M13.0M94.76K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.008.500.0023.7580.000.000.945-0.0900.002
call5.001.506.000.009.7190.000.000.856-0.0950.003
call7.500.004.900.008.8360.000.000.705-0.0720.005
call10.000.001.050.202.6385030.000.462-0.0770.006
call12.500.004.901.596.2082.000.000.561-0.1760.006
call15.000.004.900.056.65116.000.000.532-0.1950.006
call17.500.004.900.007.4080.000.000.519-0.2140.006
put2.500.004.900.0011.0990.000.00-0.056-0.0890.002
put5.000.004.900.005.8200.000.00-0.136-0.0950.003
put7.500.001.000.752.8941.000.00-0.276-0.0680.005
put10.000.104.900.007.2770.000.00-0.398-0.1430.005
put12.501.506.000.005.7860.000.00-0.614-0.1010.005
put15.004.008.500.006.5390.000.00-0.650-0.1170.005
put17.506.5011.000.007.1250.000.00-0.672-0.1290.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-264Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-23SCHEDULE 13GSEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-24SCHEDULE 13G/ASEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-06-29SCHEDULE 13G/ASEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-238-KCurrent report2026-06-16SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-22SCHEDULE 13G/ASEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-11SCHEDULE 13G/ASEC
2026-05-018-K/A2026-04-15SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-16SEC
2026-04-208-KCurrent report2026-04-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10740.03K500
2026-091.33M500
2026-08496.20K200
2026-071.59M400
2026-061.26M800
2026-05791.43K800
2026-040000
2026-031.10M1600
2026-021.03M500
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Opaleye Management Inc.18.64%
Solas Capital Management, LLC12.39%
AWM Investment Company, Inc.10.77%
Cable Car Capital, LP8.90%
Ikarian Capital, LLC5.38%
SPHERA FUNDS MANAGEMENT LTD.3.51%
ESSEX INVESTMENT MANAGEMENT CO LLC2.72%
Alyeska Investment Group, L.P.2.35%
Aristides Capital LLC1.41%
CANTOR FITZGERALD, L. P.1.40%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.09%
Avantis U.S. Small Cap Equity ETF0.03%

OakChart. ACOG. Cached 15 minutes.